D. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00

Immunic (NASDAQ:IMUX) had its price objective lowered by equities research analysts at D. Boral Capital from $10.00 to $8.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

IMUX has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, September 26th. Chardan Capital began coverage on Immunic in a report on Monday, September 29th. They set a “buy” rating and a $13.00 price objective on the stock. Roth Capital began coverage on Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.80.

Immunic Stock Performance

IMUX traded down $0.04 during trading on Thursday, reaching $0.72. The company had a trading volume of 905,740 shares, compared to its average volume of 1,287,279. The firm’s 50-day simple moving average is $0.83 and its 200 day simple moving average is $0.87. The company has a market cap of $71.42 million, a price-to-earnings ratio of -0.77 and a beta of 1.53. Immunic has a 12-month low of $0.56 and a 12-month high of $1.42.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. On average, sell-side analysts expect that Immunic will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Immunic

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Aberdeen Group plc acquired a new stake in Immunic during the first quarter worth approximately $1,155,000. 683 Capital Management LLC grew its holdings in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after buying an additional 200,000 shares in the last quarter. Jane Street Group LLC increased its position in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after buying an additional 152,726 shares during the period. Focus Partners Wealth lifted its holdings in shares of Immunic by 19.1% during the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after buying an additional 415,104 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new stake in shares of Immunic during the third quarter worth $81,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.